- Applied DNA Sciences ( NASDAQ: APDN ) said it launched monkeypox testing testing service to hospital systems and clinical labs the in New York State and in states which recognize New York's CLEP/CLIA certification for testing.
- The launch follows Applied DNA Clinical Labs' (ADCL) receiving full approval from the New York State Department of Health (NYSDOH) for its PCR-based Linea Monkeypox Virus 1.0 Assay as a laboratory developed test (LDT) to detect the Clade II variant of the monkeypox virus, APDN said in a Sept. 6 press release.
- As of Sept. 2, there were 19,962 total confirmed monkeypox/orthopoxvirus cases in the U.S., as per the U.S. CDC.
- APDN +12.27% to $3.11 premarket Sept. 6
For further details see:
Applied DNA stock rises 12% on launching monkeypox testing service in New York